Article

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signature

2023-04-09

Abstract excerpt

Precision medicine holds great promise to improve outcomes in cancer, including haematological malignancies. However, there are few biomarkers that influence choice of chemotherapy in clinical practice. In particular, multiple myeloma requires an individualized approach as there exist several active therapies, but little agreement on how and when they should be used and combined. We have previously shown that a tr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3d45ae2a-a599-5c7e-abe3-a9abf0ef586e
DOI: 10.1101/2023.04.08.23288287

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureDOI 10.1101/2023.04.08.23288287Read

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read

RNAseq-Based Machine Learning Models for Prognostication of Multiple MyelomaSemantic proximity Read

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.Semantic proximity Read

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.Semantic proximity Read

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid LeukemiaSemantic proximity Read

Functional transcriptomic landscape informs novel therapeutic strategies in multiple myelomaSemantic proximity Read

A robust gene expression signature to predict proteasome inhibitor benefit in Multiple MyelomaSemantic proximity Read

Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment.Semantic proximity Read

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read

Genetic program activity delineates risk, relapse, and therapy responsiveness in Multiple MyelomaSemantic proximity Read

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancerSemantic proximity Read

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read